FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
- Drug
- Blincyto (blinatumomab) · Anti-CD19-CD3 bispecific antibody
- Conditions
- LymphoidOther hematologic neoplasm